DGAP-News: Cytos to regain rights to Smoking Cessation Vaccine
(firmenpresse) - EquityStory AG-News: Cytos Biotechnology AG / Key word(s): Research
Update
Cytos to regain rights to Smoking Cessation Vaccine
23.01.2013 / 07:15
---------------------------------------------------------------------
Cytos to regain rights to Smoking Cessation Vaccine
Schlieren (Zurich), Switzerland, January 23, 2013 - Cytos Biotechnology Ltd
(SIX:CYTN) today announced that Novartis will discontinue the NIC002
project which is a therapeutic vaccine candidate for the treatment of
nicotine addiction. Already communicated in October 2009 were results from
a Phase 2 study with NIC002 conducted by Novartis that showed formation of
nicotine-specific antibodies in patients but did not meet its primary
endpoint of increased smoking cessation. As a result of the
discontinuation, Novartis will terminate the licence granted in 2007 and
will return to Cytos the licensed rights pursuant to the provisions of the
licence agreement.
A second collaboration with Novartis on CAD106 in development for the
treatment of patients with Alzheimer's Disease is not affected by this
decision.
The termination of the NIC002 project has no impact on Cytos' financial and
program guidance.
###
For further information, please contact:
Cytos Biotechnology Ltd
Harry Welten
Chief Financial Officer
Tel: +41 44 733 46 46
e-mail: harry.welten(at)cytos.com
US Investor enquiries
Susan A. Noonan
Tel: +1 (212) 966 3650
e-mail: susan(at)sanoonan.com
About Cytos Biotechnology Ltd
Cytos is a public biopharmaceutical company focused on the development of
targeted immuno-therapies. The Company's lead product candidate CYT003 is a
first-in-class biologic in Phase 2 clinical development as a potential new
treatment for allergic asthma.
CYT003 acts via a novel, allergen-independent mechanism of action to
selectively suppress the body's immune response to allergens, a predominant
risk factor for asthma. In a successfully completed Phase 2a study, CYT003
was shown to maintain asthma control and lung function and asthma control
in patients with persistent allergic asthma, even as standard inhaled
corticosteroid treatment was withdrawn. CYT003 has been shown to be safe in
over 450 patients to date.
Cytos was founded in 1995 as a spinoff from the Swiss Federal Institute of
Technology (ETH) in Zurich. It is located in Schlieren (Zurich),
Switzerland. The Company is listed according to the Main Standard on the
SIX Swiss Exchange Ltd under the symbol CYTN.
www.cytos.com
This foregoing press release may contain forward-looking statements that
include words or phrases such as 'are intended for', 'are designed to', or
other similar expressions. These forward-looking statements are subject to
a variety of significant uncertainties, including scientific, business,
economic and financial factors, and therefore actual results may differ
significantly from those presented. There can be no assurance that any
further therapeutic entities will enter clinical trials, that clinical
trial results will be predictive for future results, that therapeutic
entities will be the subject of filings for regulatory approval, that any
drug candidates will receive marketing approval from the U.S. Food and Drug
Administration or equivalent regulatory authorities, or that drugs will be
marketed successfully. Against the background of these uncertainties
readers should not rely on forward-looking statements. The Company assumes
no responsibility to update forward-looking statements or adapt them to
future events or developments.
End of Corporate News
---------------------------------------------------------------------
23.01.2013 This press release was distributed by EQS CORPORATE
COMMUNICATIONS.
www.eqs.com - news archive: www.eqs.com/ch/presskit
The issuer is responsible for the contents of the release.
---------------------------------------------------------------------
Language: English
Company: Cytos Biotechnology AG
Wagistr. 25
8952 Schlieren
Switzerland
Phone: +41 44 733 4747
Fax: +41 44 733 4740
E-mail: info(at)cytos.com
Internet: www.cytos.com
ISIN: CH0011025217, CH0029060735
Swiss Security Number: -
Listed: Freiverkehr in Berlin, München, Stuttgart;
Open Market in Frankfurt; SIX
End of News EquityStory AG News-Service
---------------------------------------------------------------------
199625 23.01.2013
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 23.01.2013 - 07:15 Uhr
Sprache: Deutsch
News-ID 222040
Anzahl Zeichen: 5844
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 347 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Cytos to regain rights to Smoking Cessation Vaccine"
steht unter der journalistisch-redaktionellen Verantwortung von
Cytos Biotechnology AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
